Exploring therapeutic decisions in elderly patients with non-small cell lung cancer: Results and conclusions from North central cancer treatment group study N0222

Heidi Mc Kean, Philip J. Stella, Shauna L. Hillman, Kendrith M. Rowland, Michael W. Cannon, Robert J. Behrens, Gerald G. Gross, Mark D. Sborov, Eliot L. Friedman, Aminah Jatoi

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

How do oncologists choose therapy for the elderly? Oncologists assigned patients aged 65 years or older with incurable non-small cell lung cancer to: (a) carboplatin (AUC = 2) + paclitaxel 50 mg/m2 days 1, 8, 15 (28-day cycle ×A - 4) followed by gefitinib; or (b) gefitinib 250 mg/day. With (a), 12 of 34 were progression-free at 6 months; median time to cancer progression was 3.9 months. With (b), the same occurred in 11 of 28 patients with the latter being 4.9 months. The most common reason for conventional chemotherapy was oncologists opinion that the cancer was aggressive, and for gefitinib alone, patients reluctance to receive chemotherapy. Interestingly, age had no influence.

Original languageEnglish (US)
Pages (from-to)266-271
Number of pages6
JournalCancer Investigation
Volume29
Issue number4
DOIs
StatePublished - May 2011

    Fingerprint

Keywords

  • Akt
  • Breast cancer
  • Mutation
  • PI3K
  • PIK3CA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mc Kean, H., Stella, P. J., Hillman, S. L., Rowland, K. M., Cannon, M. W., Behrens, R. J., Gross, G. G., Sborov, M. D., Friedman, E. L., & Jatoi, A. (2011). Exploring therapeutic decisions in elderly patients with non-small cell lung cancer: Results and conclusions from North central cancer treatment group study N0222. Cancer Investigation, 29(4), 266-271. https://doi.org/10.3109/07357907.2010.535061